Sunitinib-resistant KIT mutants

Stable Identifier
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Sunitinib is a class II tyrosine kinase inhibitor that is often used as a second line treatment in KIT-mutated cancers that develop resistance to imatinib (Heinrich et al, 2008; Serrano et al, 2017; reviewed in Roskoski, 2018; Corless et al, 2011).

Literature References
PubMed ID Title Journal Year
29704617 The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders

Roskoski, R

Pharmacol. Res. 2018
28478525 Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors

Serrano, C, George, S, Valverde, C, Olivares, D, García-Valverde, A, Suárez, C, Morales-Barrera, R, Carles, J

Target Oncol 2017
18955458 Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

Heinrich, MC, Maki, RG, Corless, CL, Antonescu, CR, Harlow, A, Griffith, D, Town, A, McKinley, A, Ou, WB, Fletcher, JA, Fletcher, CD, Huang, X, Cohen, DP, Baum, CM, Demetri, GD

J. Clin. Oncol. 2008
Participant Of
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!